Anti-B-Zelltherapie bei Kollagenosen

Zusammenfassung

Die B-Zell-gerichtete Therapie beschränkt sich nicht auf die B-Zell-Depletion mit monoklonalen Antikörpern, sondern viele Therapiestrategien zeigen Effekte auf B-Zellen. Trotz Zulassung von Belimumab für eine Subgruppe der SLE-Patienten sind weiterhin randomisierte Studien zur Beurteilung B-Zell-gerichteter Therapien bei schwerem und refraktärem SLE und anderen Kollagenosen erforderlich. Eine Aufnahme von Patienten mit seltenen Erkrankungen in Register zur Erfassung der Effektivität und Sicherheit berücksichtigt werden sollte, wenn diese Biologika außerhalb der Indikation erhalten (für Deutschland: www.graid.de).

Abstract

B cells are able to present antigen, secrete cytokines and differentiate into (auto)antibody secreting cells and are therefore considered as an important therapeutic target in patients with autoantibody-mediated autoimmune disease. Benefits and limitations of B-cell-directed therapies and unmet medical needs are discussed in this minireview. B cell targeting broadens our armamentarium available to treat SLE and other connective tissue diseases. But further research addressing unmet medical needs is required and refractory patients receiving B cell-directed off-label therapeutics should be enrolled in registries to collect information on the value and safety of these drugs in rare autoimmune diseases.

Schlüsselwörter

Kollagenosen - Biologika - Anti-B-Zell-Therapie

Keywords

connective tissue diseases - biologicals - B-cell-directed therapies

• Literatur

• 1 Abdulahad WH et al. Immune regulation and B-cell depletion therapy in patients with primary Sjogren's syndrome. J Autoimmun 2012; 39: 103-111
• 2 Aringer M et al. Current state of evidence on "off label" therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria, and Switzerland – a consensus report. Lupus 2012; 21: 386-401
• 3 Díaz-Lagares C, Croca S, Sangle S et al. The UK-BIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmun Rev 2011; 11: 357-364
• 4 Bosello S et al. B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 2011; 10: 624-630
• 5 Buch MH et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 909-920
• 6 Chan TM et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162
• 7 Dooley MA. ALMS Group et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365: 1886-1895
• 8 Dorner T et al. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J Immunol Methods 2011; 363: 187-197
• 9 Erkan D et al. Rituximab in antiphospholipid ayndrome (RITAPS) – A pilot open-label phase II prospective trial for non-criteria manifestations of antiphospholipid antibodies (aPL). . 11th Annual Scientific Meeting of the American College of Rheumatology Chicago 2011, Presentation Number 727
• 10 Espinosa G et al. Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev 2011; 10: 664-668
• 11 Ginzler EM et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228
• 12 Ioannou Y et al. B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres. Ann Rheum Dis 2008; 67: 425-426
• 13 Karnell JL et al. Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation. J Immunol 2011; 187: 3603-3612
• 14 Mahler EA et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford) 2011; 50: 2206-2213
• 15 Merrill JT et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233
• 16 Molloy ES. PML and rheumatology: the contribution of disease and drugs. Cleve Clin J Med 2011; 78 (Suppl. 02) 28-32
• 17 Mysler EF et al. Efficacy and safety of ocrelizumab, a humanized antiCD20 antibody, in patients with active proliferative lupus nephritis (LN): Results from the randomized, double-blind phase III BELONG Sstudy. [Abstract]. Arthritis Rheum 2010; 62 (Suppl. 10) 1455
• 18 Neubert K et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748-755
• 19 Rovin BH, Furie R, Latinis K. for the LUNAR Investigator Group et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab (LUNAR) study. Arthritis Rheum 2012; 64: 1215-1226
• 20 Tashkin DP et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-2666
• 21 Terrier B et al. Club Rhumatismes et Inflammation Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010; 62: 2458-2466
• 22 Tony HP. GRAID investigators et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011; 13: R75